Barclays PLC Sells 5,731 Shares of Kodiak Sciences Inc. (NASDAQ:KOD)

Barclays PLC reduced its stake in Kodiak Sciences Inc. (NASDAQ:KOD) by 7.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 73,927 shares of the company’s stock after selling 5,731 shares during the quarter. Barclays PLC owned about 0.14% of Kodiak Sciences worth $736,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the stock. PNC Financial Services Group Inc. lifted its position in shares of Kodiak Sciences by 1,501.5% in the 4th quarter. PNC Financial Services Group Inc. now owns 3,187 shares of the company’s stock worth $32,000 after purchasing an additional 2,988 shares during the period. US Bancorp DE acquired a new position in Kodiak Sciences in the fourth quarter valued at $40,000. Headlands Technologies LLC bought a new stake in Kodiak Sciences during the fourth quarter valued at $90,000. Fox Run Management L.L.C. acquired a new stake in Kodiak Sciences during the 4th quarter worth about $118,000. Finally, SG Americas Securities LLC raised its position in shares of Kodiak Sciences by 61.4% in the 4th quarter. SG Americas Securities LLC now owns 20,684 shares of the company’s stock worth $206,000 after acquiring an additional 7,871 shares in the last quarter. 89.06% of the stock is currently owned by institutional investors.

Kodiak Sciences Trading Down 22.6 %

NASDAQ:KOD opened at $3.81 on Wednesday. Kodiak Sciences Inc. has a 12 month low of $1.92 and a 12 month high of $11.60. The stock has a market capitalization of $200.99 million, a price-to-earnings ratio of -1.04 and a beta of 2.42. The firm has a fifty day simple moving average of $3.28 and a two-hundred day simple moving average of $5.49.

Kodiak Sciences (NASDAQ:KOD) last issued its earnings results on Thursday, March 27th. The company reported ($0.84) EPS for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.06. Equities analysts predict that Kodiak Sciences Inc. will post -3.45 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “neutral” rating and set a $3.00 target price on shares of Kodiak Sciences in a research note on Monday, March 31st.

About Kodiak Sciences

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.